Preemptive Action: Reducing the Risk of Breast Cancer

Elena Beyzarov, PharmD
Published Online: Thursday, June 14, 2012
Follow Pharmacy_Times:
Pharmacy Times Office of Continuing Professional Education


Preemptive Action: Reducing the Risk of Breast Cancer

Elena Beyzarov, PharmD

Scientific Director Pharmacy Times Office of Continuing Professional Education

Elena Beyzarov, PharmD, has no relevant affiliations or financial relationships with commercial interests to disclose related to this activity

Pharmacy Times Office of Continuing Professional Education Planning Staff

Judy V. Lum, MPA, and Ann C. Lichti, CCMEP have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Editorial

Bea Riemschneider, Jennifer Barrio, and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity


Educational Objectives

Upon completion of this educational activity, participants should be able to:
  1. Describe the current incidence and prevalence of breast cancer among American women.
  2. Examine factors associated with increased risk of breast cancer, including lifestyle, genetic factors, and hormone replacement therapy.
  3. Examine factors associated with decreased risk of breast cancer, focusing on chemoprevention strategies.
  4. Discuss implications for pharmacists in regard to addressing common patient questions on breast cancer risks and providing evidence-based information on chemoprevention and use of dietary supplements.

Target Audience: Pharmacists

Type of Activity: Knowledge

Release date: June 10, 2012

Expiration date: June 10, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online at www.PharmacyTimes.com. There is a nominal fee of $10.00 for mailed/faxed evaluation and exam forms.

Click here to view this activity



Related Articles
Community pharmacists play a significant role in helping patients to maintain the health of their skin.
Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.
AbbVie, Roche, and Genentech are collectively developing the drug to treat relapsed or refractory CLL patients with the 17p deletion genetic mutation.
Teva is voluntarily recalling select lots of intravenous fluorouracil (Adrucil).
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$